Advances in Prostate‐Specific Membrane Antigen (PSMA)‐Targeted Phototheranostics of Prostate Cancer

H Wang, Z He, XA Liu, Y Huang, J Hou… - Small …, 2022 - Wiley Online Library
With the advent of the era of precision medicine, prostate‐specific membrane antigen
(PSMA)‐targeted theranostic strategies have had a profound impact on prostate cancer …

[HTML][HTML] [68Ga] Ga-PSMA-11 in prostate cancer: a comprehensive review

F Bois, C Noirot, S Dietemann, IC Mainta… - American Journal of …, 2020 - ncbi.nlm.nih.gov
Imaging of the prostate-specific membrane antigen (PSMA) has become an important tool
for managing patients with recurrent prostate cancer, and one of the most frequently …

18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm …

J Calais, F Ceci, M Eiber, TA Hope, MS Hofman… - The Lancet …, 2019 - thelancet.com
Summary Background National Comprehensive Cancer Network guidelines consider 18 F-
fluciclovine PET-CT for prostate cancer biochemical recurrence localisation after radical …

Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a …

J Kuten, I Fahoum, Z Savin, O Shamni… - Journal of Nuclear …, 2020 - Soc Nuclear Med
18F-PSMA-1007 is a novel prostate-specific membrane antigen (PSMA)–based
radiopharmaceutical for imaging prostate cancer (PCa). The aim of this study was to …

68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment …

A Farolfi, F Ceci, P Castellucci, T Graziani… - European journal of …, 2019 - Springer
Purpose The primary aim of this retrospective, single-centre analysis was to assess the
performance of 68 Ga-PSMA-11 PET/CT in prostate cancer (PCa) patients in early PSA …

[HTML][HTML] Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]

J Calais, J Czernin, WP Fendler, D Elashoff… - BMC cancer, 2019 - Springer
Background Salvage radiotherapy (SRT) for prostate cancer (PCa) recurrence after
prostatectomy offers long-term biochemical control in about 50–60% of patients. SRT is …

A prospective head-to-head comparison of 18F-fluciclovine with 68Ga-PSMA-11 in biochemical recurrence of prostate cancer in PET/CT

B Pernthaler, R Kulnik, C Gstettner… - Clinical nuclear …, 2019 - journals.lww.com
Purpose One of the major challenges for all imaging modalities is accurate detection of
prostate cancer (PCa) recurrence. Beyond the established 68 Ga-PSMA, a novel promising …

[HTML][HTML] Cyclotron-based production of 68Ga, [68Ga]GaCl3, and [68Ga]Ga-PSMA-11 from a liquid target

ME Rodnick, C Sollert, D Stark, M Clark… - EJNMMI …, 2020 - Springer
Purpose To optimize the direct production of 68 Ga on a cyclotron, via the 68 Zn (p, n) 68 Ga
reaction using a liquid cyclotron target. We Investigated the yield of cyclotron-produced 68 …

Update on 18F-fluciclovine PET for prostate cancer imaging

EE Parent, DM Schuster - Journal of Nuclear Medicine, 2018 - Soc Nuclear Med
PET is a functional imaging method that can exploit various aspects of tumor biology to
enable greater detection of prostate cancer than can be provided by morphologic imaging …

68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy

F Ceci, P Castellucci, T Graziani, A Farolfi… - European Journal of …, 2019 - Springer
Objectives The primary objective was the evaluation of Gallium 68 (68 Ga)-prostate-specific
membrane antigen (PSMA)-11 positron emission tomography/computed tomography …